Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+channel,IKCa1: A potential immunosuppressant
Top Cited Papers
Open Access
- 5 July 2000
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 97 (14), 8151-8156
- https://doi.org/10.1073/pnas.97.14.8151
Abstract
The antimycotic clotrimazole, a potent inhibitor of the intermediate-conductance calcium-activated K+ channel, IKCa1, is in clinical trials for the treatment of sickle cell disease and diarrhea and is effective in ameliorating the symptoms of rheumatoid arthritis. However, inhibition of cytochrome P450 enzymes by clotrimazole limits its therapeutic value. We have used a rational design strategy to develop a clotrimazole analog that selectively inhibits IKCa1 without blocking cytochrome P450 enzymes. A screen of 83 triarylmethanes revealed the pharmacophore for channel block to be different from that required for cytochrome P450 inhibition. The “IKCa1-pharmacophore” consists of a (2-halogenophenyl)diphenylmethane moiety substituted by an unsubstituted polar π-electron-rich heterocycle (pyrazole or tetrazole) or a −C N group, whereas cytochrome P450 inhibition absolutely requires the imidazole ring. A series of pyrazoles, acetonitriles, and tetrazoles were synthesized and found to selectively block IKCa1. TRAM-34 (1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) inhibits the cloned and the native IKCa1 channel in human T lymphocytes with a Kd of 20–25 nM and is 200- to 1,500-fold selective over other ion channels. Using TRAM-34, we show that blocking IKCa1 in human lymphocytes, in the absence of P450-inhibition, results in suppression of mitogen-stimulated [3H]thymidine incorporation of preactivated lymphocytes with EC50-values of 100 nM-1 μM depending on the donor. Combinations of TRAM-34 and cyclosporin A are more effective in suppressing lymphocyte mitogenesis than either compound alone. Our studies suggest that TRAM-34 and related compounds may hold therapeutic promise as immunosuppressants.Keywords
This publication has 37 references indexed in Scilit:
- Amino Acid 305 Determines Catalytic Center Accessibility in CYP3A4Biochemistry, 2000
- ShK-Dap22, a Potent Kv1.3-specific Immunosuppressive PolypeptideJournal of Biological Chemistry, 1998
- The Structure of the Potassium Channel: Molecular Basis of K + Conduction and SelectivityScience, 1998
- The antifungal antibiotic, clotrimazole, inhibits chloride secretion by human intestinal T84 cells via blockade of distinct basolateral K+ conductances. Demonstration of efficacy in intact rabbit colon and in an in vivo mouse model of cholera.JCI Insight, 1997
- Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.JCI Insight, 1996
- Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology.The Journal of general physiology, 1993
- Clotrimazole in rheumatoid arthritis.Annals Of The Rheumatic Diseases, 1980
- ClotrimazoleDrugs, 1975
- N-Trisubstituted Methylimidazoles as Antifungal AgentsJournal of Pharmaceutical Sciences, 1973
- Notiz über eine einfache Herstellungsweise von DiphenylacetonitrilEuropean Journal of Inorganic Chemistry, 1953